NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Testing
NCCN Guidelines® recommend testing eligible patients with resectable Stage IB-IIIA NSCLC for EGFR mutations and also recommend broader, more comprehensive biomarker testing at diagnosis of certain patients with metastatic NSCLC to help determine appropriate treatment options.14,15 Diagnostic and biomarker testing require a multidisciplinary approach, with appropriate sample acquisition and handling.16,17 In resectable Stages IB-IIIA NSCLC, surgical tissue or biopsy specimens may be used for testing.14 For eligible patients with metastatic NSCLC, histologic, cytologic, and liquid biopsy (plasma testing) specimens may be used for molecular testing, and when clinically feasible, know all biomarker test results for actionable biomarkers before initiating first-line treatment.14,18